Keros Therapeutics : Press release dated June 9, 2023 - Form

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual... | June 9, 2023

Related Keywords

Justin Frantz , Jasbirs Seehra , Exchange Commission , Company Nasdaq , Keros Therapeutics Inc , Company Quarterly Report On Form , Inhibitor Program , European Hematology Association , Keros Therapeutics Presents Clinical Trial , Preclinical Study Results , Preclinical Data , Annual Congress , Keros Therapeutics , Chief Executive Officer , Ongoing Phase , Webcast Information , Private Securities Litigation Reform Act , Quarterly Report , Nc Stock Exchange , News , Information , Press Release , Heros , Herapeutics , Presents , Linical , Trial , End , Reclinical , Study , Results , Rom , Its , Program , Data , Lk2 , Inhibitor , It , The , 8th Kros Us4923271013 ,